Yvonne Greenstreet sold $16M of ALNY
Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC.. 50,937 shares at an average of $305.00, traded May 30, 2025, filed Jun 3, 2025.
Score components
- +25RoleCEO
- +25Trade size$15.5M at market
- +20Share of holdings soldSold 63% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000075, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 30, 2025 | MOption exercise Common Stock10b5-1 | +12,081 | $119.13 | $1.4M | 61,029 | Jun 3, 2025 |
| May 30, 2025 | MOption exercise Common Stock10b5-1 | +19,559 | $118.05 | $2.3M | 80,588 | Jun 3, 2025 |
| May 30, 2025 | SOpen-market sale Common Stock10b5-1 | -25,469 | $304.00 | $7.7M | 55,119 | Jun 3, 2025 |
| May 30, 2025 | SOpen-market sale Common Stock10b5-1 | -6,171 | $306.00 | $1.9M | 48,948 | Jun 3, 2025 |
| Jun 2, 2025 | MOption exercise Common Stock10b5-1 | +12,080 | $119.13 | $1.4M | 61,028 | Jun 3, 2025 |
| Jun 2, 2025 | MOption exercise Common Stock10b5-1 | +7,217 | $118.05 | $852k | 68,245 | Jun 3, 2025 |
| Jun 2, 2025 | SOpen-market sale Common Stock10b5-1 | -19,297 | $306.00 | $5.9M | 48,948 | Jun 3, 2025 |
| May 30, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -19,559 | $0.00 | $0 | 8,064 | Jun 3, 2025 |
| Jun 2, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -7,217 | $0.00 | $0 | 847 | Jun 3, 2025 |
| May 30, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -12,081 | $0.00 | $0 | 12,919 | Jun 3, 2025 |
| Jun 2, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -12,080 | $0.00 | $0 | 839 | Jun 3, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $5.5M 12,128 shares | -36% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $12M 25,650 shares | -32% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $2.7M 5,959 shares | -23% | |
| 55Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 2,441 shares | -9% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $635k 1,405 shares | -5% | |
| 70Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $4.0M 8,924 shares | -12% | |
| 62Notable | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $1.7M 3,821 shares | -7% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8.4M 18,000 shares | -96% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $1.6M 3,474 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.